Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Anticoagulants

Concept
uri icon
  • Overview
scroll to property group menus

Overview

subject area of

  • A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: Factoring in new trials and meta-analysis data  Academic Article
  • Abciximab therapy and unplanned coronary stent deployment - favorable effects on stent use, clinical outcomes, and bleeding complications  Academic Article
  • Activated protein C  Academic Article
  • Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions  Academic Article
  • Activated protein C reduces graft neutrophil activation in clinical renal transplantation  Academic Article
  • Activated protein C resistance: What have we learned now that the dust has settled?  Academic Article
  • Activated protein C targets CD8(+) dendritic cells to reduce the mortality of endotoxemia in mice  Academic Article
  • Activated protein C variants with normal cytoprotective but reduced anticoagulant activity  Academic Article
  • Activated protein C-dependent and -independent anticoagulant activities of protein S have different structural requirements  Academic Article
  • Activated protein C: biased for translation  Academic Article
  • Activation of protein C and hemodynamic recovery after coronary artery bypass surgery  Academic Article
  • Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data  Academic Article
  • Adjunctive therapy for percutaneous revascularization in acute myocardial infarction  Academic Article
  • American College of Medical Genetics consensus statement on factor V Leiden mutation testing  Academic Article
  • An activated protein c analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents  Academic Article
  • An antitissue factor monoclonal-antibody which inhibits tf-viia complex is a potent anticoagulant in plasma  Academic Article
  • An engineered Factor Va prevents bleeding induced by anticoagulant wt activated protein C  Academic Article
  • Anticoagulant dysfunction of human Arg352Trp-activated protein C caused by defective factor Va inactivation  Academic Article
  • Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys  Academic Article
  • Anticoagulant synergism of heparin and activated protein C in vitro - role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C  Academic Article
  • Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease  Academic Article
  • Antiplatelet and anticoagulant use after myocardial infarction  Academic Article
  • Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model  Academic Article
  • Antithrombotic therapy with intracoronary stenting  Academic Article
  • Aspirin dose and six-month outcome after an acute coronary syndrome  Academic Article
  • Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein iib/iiia inhibition with eptifibatide in patients with acute coronary syndromes - observations from the platelet iib/iiia in unstable angina: Receptor suppression using integrilin therapy (pursuit) trial  Academic Article
  • Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va  Academic Article
  • Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va  Academic Article
  • Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention - replace-2 randomized trial  Academic Article
  • Bivalirudin versus heparin and glycoprotein iib/iiia inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the replace-2 trial)  Academic Article
  • Bivalirudin vs heparin in percutaneous coronary intervention: A pooled analysis  Academic Article
  • Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the comparison of abciximab complications with hirulog for ischemic events trial (cachet)  Academic Article
  • Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention  Academic Article
  • Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes  Academic Article
  • Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S  Academic Article
  • Cholesterol enhances phospholipid-dependent activated protein c anticoagulant activity  Academic Article
  • Clinical outcomes of bivalirudin for ischemic heart disease  Academic Article
  • Clinical-studies of protein-C  Academic Article
  • Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of pci linking angiomax to reduced clinical events replace -1 trial)  Academic Article
  • Contemporary clinical-trials of restenosis  Academic Article
  • Continuing education course #2: Current understanding of hemostasis  Academic Article
  • Creatine kinase-mb elevation after coronary artery bypass grafting surgery in patients with non-st-segment elevation acute coronary syndromes predict worse outcomes: Results from four large clinical trials  Academic Article
  • Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes  Academic Article
  • Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition  Academic Article
  • Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes  Academic Article
  • Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C  Academic Article
  • Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants  Academic Article
  • Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa  Academic Article
  • Direct anticoagulant activity of protein S-C4b binding protein complex in heerlen heterozygotes and normals  Academic Article
  • Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions  Academic Article
  • Direct thrombin inhibitors in acute coronary syndromes: Effect in patients undergoing early percutaneous coronary intervention  Academic Article
  • Dissociation of lpl and ldl: Effects of lipoproteins and anti-apob antibodies  Academic Article
  • Economic assessment of platelet glycoprotein iib/iiia inhibition for prevention of ischemic complications of high-risk coronary angioplasty  Academic Article
  • Economic evaluation of bivalirudin with provisional glycoprotein iib/iiia inhibition versus heparin with routine glycoprotein iib/iiia inhibition for percutaneous coronary intervention - results from the replace-2 trial  Academic Article
  • Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation the mSToPS randomized clinical trial  Academic Article
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the gusto-iii trial)  Academic Article
  • Effects of integrelin, a platelet glycoprotein iib/iiia receptor antagonist, in unstable angina - a randomized multicenter trial  Academic Article
  • Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke  Academic Article
  • Engineered recombinant factor vii q(217) variants with altered inhibitor specificities  Academic Article
  • Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients  Academic Article
  • Enoxaparin in primary and facilitated percutaneous coronary intervention a formal prospective nonrandomized substudy of the finesse trial (facilitated intervention with enhanced reperfusion speed to stop events)  Academic Article
  • Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry  Academic Article
  • Evolution of improved antithrombotic and antiplatelet agents: Genesis of the comparison of abciximab complications with hirulog and back-up abciximab events trial (cachet)  Academic Article
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction - results from the speed (gusto-4 pilot) trial  Academic Article
  • First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity  Academic Article
  • Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles  Academic Article
  • Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms  Academic Article
  • Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction  Academic Article
  • Heparin-induced thrombocytopenia  Academic Article
  • Heparin-induced thrombocytopenia and cardiovascular diseases  Academic Article
  • High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C  Academic Article
  • Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial  Academic Article
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial  Academic Article
  • Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein c system  Academic Article
  • Incidence and prevention of ischemic stroke following myocardial infarction: review of current literature  Academic Article
  • Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral-artery injury model  Academic Article
  • Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity  Academic Article
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial  Academic Article
  • Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2  Academic Article
  • Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor  Academic Article
  • Interactions and inhibition of blood-coagulation factor-Va involving residues 311-325 of activated protein-C  Academic Article
  • Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C  Academic Article
  • International, randomized, controlled trial of lamifiban (a platelet glycoprotein iib/iiia inhibitor), heparin, or both in unstable angina  Academic Article
  • Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials  Academic Article
  • Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial  Academic Article
  • JLK isocoumarin inhibitors: Selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo  Academic Article
  • Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein iib/iiia blockade compared to heparin with routine glycoprotein iib/iiia blockade - a replace-2 substudy  Academic Article
  • Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates  Academic Article
  • Local drug delivery systems and prevention of restenosis  Academic Article
  • Long-term efficacy of bivalirudin and provisional glycoprotein iib/iiia blockade vs heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary revascularization - replace-2 randomized trial  Academic Article
  • Long-term mortality of patients with acute myocardial infarction in the united states and canada - comparison of patients enrolled in global utilization of streptokinase and t-pa for occluded coronary arteries (gusto)-i  Academic Article
  • Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway  Academic Article
  • N-CAM binding inhibits the proliferation of hippocampal progenitor cells and promotes their differentiation to a neuronal phenotype  Academic Article
  • N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease - a global utilization of strategies to open occluded arteries (gusto)-iv substudy  Academic Article
  • Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity  Academic Article
  • Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice  Academic Article
  • Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S  Academic Article
  • Neutrophils release brakes of coagulation  Academic Article
  • Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va  Academic Article
  • Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors  Academic Article
  • Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the randomized evaluation in pci linking angiomax to reduced clinical events (replace-2) trial  Academic Article
  • Patient stratification and its predictive value for cardiac events  Academic Article
  • Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention  Academic Article
  • Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers  Academic Article
  • Planned versus provisional use of glycoprotein iib/iiia inhibitors in smokers undergoing percutaneous' coronary intervention  Academic Article
  • Plasma contains protein S monomers and multimers with similar direct anticoagulant activity  Academic Article
  • Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor  Academic Article
  • Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation  Academic Article
  • Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes - gradient of benefit related to the revascularization strategy  Academic Article
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization  Academic Article
  • Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease  Academic Article
  • Platelet glycoprotein iib/iia receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy  Academic Article
  • Practice patterns and outcomes of percutaneous coronary interventions in the united states: 1995 to 1997  Academic Article
  • Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke  Academic Article
  • Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage  Academic Article
  • Primary percutaneous coronary intervention vs. Fibrinolytic therapy for acute st-elevation myocardial infarction in the elderly  Academic Article
  • Promise of combined low-molecular-weight heparin and platelet glycoprotein iib/iiia inhibition: Results from platelet iib/iiia antagonist for the reduction of acute coronary syndrome events in a global organization network b (paragon b)  Academic Article
  • Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities  Academic Article
  • Protein S confers neuronal protection during ischemic/hypoxic injury in mice  Academic Article
  • Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity  Academic Article
  • Protein S multimers and monomers each have direct anticoagulant activity  Academic Article
  • Protein c anticoagulant and cytoprotective pathways  Academic Article
  • Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets  Academic Article
  • Recent advances in anticoagulant therapy for acute coronary syndromes  Academic Article
  • Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model  Academic Article
  • Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials  Academic Article
  • Reevaluation of total, free, and bound protein-S and C4b-binding protein-levels in plasma anticoagulated with citrate or hirudin  Academic Article
  • Relationship between activated clotting time and ischemic or hemorrhagic complications - analysis of 4 recent randomized clinical trials of percutaneous coronary intervention  Academic Article
  • Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction - results from the global use of strategies to open occluded arteries in acute coronary syndromes (gusto-iib) trial  Academic Article
  • Relative antithrombotic and andhernostatic effects of protein C activator versus low-molecular-weight heparin in primates  Academic Article
  • Resistance to activated protein C: A common inherited cause of venous thrombosis  Academic Article
  • Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation  Academic Article
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention  Academic Article
  • Role of the PROS1 gene in thrombosis: lessons and controversies  Academic Article
  • Role of zymogen and activated factor x as scaffolds for the inhibition of the blood coagulation factor viia-tissue factor complex by recombinant nematode anticoagulant protein c2  Academic Article
  • Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition  Academic Article
  • Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency  Academic Article
  • Science review: Role of coagulation protease cascades in sepsis  Academic Article
  • Selection of thrombolytic therapy for individual patients: Development of a clinical model  Academic Article
  • Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates  Academic Article
  • Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity  Academic Article
  • Species-specific anticoagulant and mitogenic activities of murine protein S  Academic Article
  • Specificity of coagulation factor signaling  Academic Article
  • Sphingolipids as bioactive regulators of thrombin generation  Academic Article
  • Stenting for ischemic heart disease  Academic Article
  • The anticoagulant function of coagulation factor v  Academic Article
  • The frequency of type-I heterozygous protein-S and protein-C deficiency in 141 unrelated young-patients with venous thrombosis  Academic Article
  • The impact of fibrinolytic therapy for st-segment-elevation acute myocardial infarction  Academic Article
  • The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice  Academic Article
  • Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The hero-2 randomised trial  Academic Article
  • Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials  Academic Article
  • Tissue factor and protease-activated receptor signaling in cancer  Academic Article
  • Total chemical synthesis of enzymatically active human type II secretory phospholipase A2  Academic Article
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction  Academic Article
  • Upregulation of the antithrombotic protein C pathway at birth  Academic Article
  • Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of gusto-i  Academic Article
  • Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus - an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (replace)-2 trial  Academic Article
  • Warfarin pharmacogenomics: A big step forward for individualized medicine: enlightened dosing of warfarin  Academic Article
  • Zn(2+)-containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor  Academic Article

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support